ICICI Direct Tags Emcure Pharma As High-Conviction Buy

ICICI Direct has recommended Emcure Pharma as a high-conviction 'Buy' citing the company's strong international front-end capabilities built through acquisitions in Canada and Europe. The brokerage highlighted Emcure's vertically integrated supply chain anchored by its Indian manufacturing base as a key strength. This bullish call underscores growing analyst confidence in Emcure's global expansion strategy. The recommendation signals positive momentum for the pharmaceutical stock in domestic markets.